EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Tenofovir alafenamide versus entecavir for treating hepatitis B virus-related acute-on-chronic liver failure: real-world study

Wenting Peng, Huimin Gu, Da Cheng, Keyu Chen, Cichun Wu, Chuan Jiang, Jinqing Liu, Shifang Peng, Lei Fu

Frontiers in Microbiology · 25.05.2023 · 14

DOI: 10.3389/fmicb.2023.1185492 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Frontiers in Microbiology, online erschienen am 25.05.2023. Verfasst von Wenting Peng und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Infectious Diseases, Xiangya Hospital, Central South University, Changsha, Hunan, China. Die Arbeit wurde bisher 23-mal zitiert (Crossref) und nennt 29 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background and aims Real-world data regarding hepatitis B virus-related acute-on-chronic liver failure (HBV-ACLF) patients receiving tenofovir alafenamide (TAF) as an antiviral drug are limited. Hence, we evaluated the efficacy and kidney safety of TAF among this population.

Methods

A total of 272 HBV-related ACLF patients hospitalized at Xiangya Hospital of Central South University were enrolled in this retrospective research. All patients received antiviral therapy with TAF ( n = 100) or ETV ( n = 172) and comprehensive medical treatments.

Results

Through 1:1 propensity score matching, 100 patients were finally included in each group. At week 48, the survival rates without transplantation of the TAF group and ETV group were 76.00 and 58.00%, separately ( P = 0.007). After 4 weeks of treatment, the TAF treatment group exhibited a significantly decline in HBV DNA viral load ( P = 0.029). The mean estimated glomerular filtration rate was apparently improved in the TAF group compared with the ETV group (TAF 5.98 ± 14.46 vs. ETV 1.18 ± 18.07 ml/min/1.73 m 2 ) ( P < 0.05). There were 6 patients in TAF group and 21 patients in ETV group with chronic kidney disease (CKD) stage progression ≥ 1. By contrast, the ETV treatment group has a greater risk of renal function progression in CKD 1 stage patients ( P < 0.05).

Conclusion

This real-world clinical study showed that TAF is more effective than ETV in reducing viral load and improving survival rate in HBV-ACLF patients and the risk of renal function decline is lower. Clinical trial registration https://ClinicalTrials.gov , identifier NCT05453448.

Schlagwörter

Stichwörter der Autor:innen

acute-on-chronic liver failureefficacyhepatitis B viruskidney functiontenofovir alafenamide

Autor:innen und Institutionen

  • Department of Infectious Diseases, Xiangya Hospital, Central South University, Changsha, Hunan, China.

Zitieren

APA

Peng, W., Gu, H., Cheng, D., Chen, K., Wu, C., Jiang, C., Liu, J., Peng, S., & Fu, L. (2023). Tenofovir alafenamide versus entecavir for treating hepatitis B virus-related acute-on-chronic liver failure: real-world study. Frontiers in Microbiology, 14. https://doi.org/10.3389/fmicb.2023.1185492

Vancouver

Peng W, Gu H, Cheng D, Chen K, Wu C, Jiang C, et al. Tenofovir alafenamide versus entecavir for treating hepatitis B virus-related acute-on-chronic liver failure: real-world study. Frontiers in Microbiology. 2023;14. doi:10.3389/fmicb.2023.1185492

BibTeX
@article{Peng2023,
  author = {Peng, Wenting and Gu, Huimin and Cheng, Da and Chen, Keyu and Wu, Cichun and Jiang, Chuan and Liu, Jinqing and Peng, Shifang and Fu, Lei},
  title = {Tenofovir alafenamide versus entecavir for treating hepatitis B virus-related acute-on-chronic liver failure: real-world study},
  journal = {Frontiers in Microbiology},
  year = {2023},
  volume = {14},
  doi = {10.3389/fmicb.2023.1185492}
}
Kostenlos starten →